MX2012003389A - Moduladores de gpr40 de pirrolidina. - Google Patents

Moduladores de gpr40 de pirrolidina.

Info

Publication number
MX2012003389A
MX2012003389A MX2012003389A MX2012003389A MX2012003389A MX 2012003389 A MX2012003389 A MX 2012003389A MX 2012003389 A MX2012003389 A MX 2012003389A MX 2012003389 A MX2012003389 A MX 2012003389A MX 2012003389 A MX2012003389 A MX 2012003389A
Authority
MX
Mexico
Prior art keywords
gpr40 modulators
pyrrolidine
pyrrolidine gpr40
modulators
compounds
Prior art date
Application number
MX2012003389A
Other languages
English (en)
Inventor
William R Ewing
Bruce A Ellsworth
Elizabeth A Jurica
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2012003389A publication Critical patent/MX2012003389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I): (ver fórmula (I)) o un estereoisómero, o una sal farmacéuticamente aceptable de los mismos, en la que todas las variables son que se han definido anteriormente. Estos compuestos son moduladores de receptor acoplados a proteínas G GPR40 que se pueden usar como medicamentos.
MX2012003389A 2009-10-06 2010-10-05 Moduladores de gpr40 de pirrolidina. MX2012003389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24889609P 2009-10-06 2009-10-06
PCT/US2010/051389 WO2011044073A1 (en) 2009-10-06 2010-10-05 Pyrrolidine gpr40 modulators

Publications (1)

Publication Number Publication Date
MX2012003389A true MX2012003389A (es) 2012-04-10

Family

ID=43242297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003389A MX2012003389A (es) 2009-10-06 2010-10-05 Moduladores de gpr40 de pirrolidina.

Country Status (13)

Country Link
US (1) US8288404B2 (es)
EP (1) EP2486005B1 (es)
JP (1) JP2013506714A (es)
KR (1) KR20120104534A (es)
CN (1) CN102639495A (es)
AR (1) AR078542A1 (es)
AU (1) AU2010303670A1 (es)
BR (1) BR112012007979A2 (es)
CA (1) CA2777041A1 (es)
MX (1) MX2012003389A (es)
RU (1) RU2012118504A (es)
TW (1) TW201116510A (es)
WO (1) WO2011044073A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011332198A1 (en) 2010-11-24 2013-07-11 Allergan, Inc. Modulators of S1P receptors
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
MX2015005858A (es) 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX358499B (es) 2012-11-16 2018-08-23 Bristol Myers Squibb Co Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
JP6322202B2 (ja) * 2012-11-16 2018-05-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピロリジンｇｐｒ４０修飾因子
EP2925726B1 (en) * 2012-11-16 2016-10-26 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US11104668B2 (en) 2013-12-13 2021-08-31 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
TWI659951B (zh) * 2014-05-07 2019-05-21 美商必治妥美雅史谷比公司 吡咯啶ｇｐｒ４０調節劑
US10301260B2 (en) * 2014-05-07 2019-05-28 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
CN110023298B (zh) * 2016-11-24 2022-12-16 浙江迈同生物医药有限公司 异柠檬酸脱氢酶(idh)抑制剂
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
CN111253223A (zh) * 2020-03-20 2020-06-09 重庆医科大学 一类大位阻三芳基甲烷衍生物及其合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10309929B4 (de) * 2003-03-07 2006-02-23 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators

Also Published As

Publication number Publication date
BR112012007979A2 (pt) 2016-03-29
CN102639495A (zh) 2012-08-15
CA2777041A1 (en) 2011-04-14
US20110082165A1 (en) 2011-04-07
JP2013506714A (ja) 2013-02-28
AR078542A1 (es) 2011-11-16
WO2011044073A1 (en) 2011-04-14
EP2486005A1 (en) 2012-08-15
KR20120104534A (ko) 2012-09-21
AU2010303670A1 (en) 2012-03-29
TW201116510A (en) 2011-05-16
US8288404B2 (en) 2012-10-16
EP2486005B1 (en) 2014-06-18
RU2012118504A (ru) 2013-11-20

Similar Documents

Publication Publication Date Title
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX2015005735A (es) Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
PH12017501426A1 (en) Derivatives of betulin
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
JO3297B1 (ar) تركيبات و طرق لتعديل fxr
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
PH12016502034B1 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
MY187718A (en) Pharmaceutical formulations
TN2012000248A1 (en) Novel spiropiperidine compounds
IN2014CN03803A (es)
TN2011000585A1 (en) Lxr modulators
MX2011011776A (es) Nuevos profarmacos de triptolite.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
JO2979B1 (en) Cyclopropyl compounds
EA201170509A1 (ru) Селективный модулятор рецепторов эстрогена

Legal Events

Date Code Title Description
FA Abandonment or withdrawal